论文部分内容阅读
目的:分析中药艾迪注射液联合肝动脉介入治疗法治疗肝癌的临床疗效。方法:收集我院2010年1月-2012年2月诊治的78例肝癌患者作为研究对象,根据患者的治疗方式将其分为中药联合组(39例)与介入治疗组(39例),介入治疗组患者单纯采用肝动脉介入治疗法治疗,中药联合组采用中药艾迪注射液联合肝动脉介治疗法治疗,观察患者的治疗效果、平均生存期、一年生存率和两年生存率。结果:中药联合组患者的治疗效果明显优于介入治疗组(P<0.05),平均生存期明显长于介入治疗组(P<0.05),一年生存率和两年生存率明显高于介入治疗组(P<0.05)。结论:中药艾迪注射液联合肝动脉介入治疗法治疗肝癌具有良好的临床疗效。
Objective: To analyze the curative effect of traditional Chinese medicine Aidi injection combined with hepatic artery interventional therapy on hepatocellular carcinoma. Methods: Totally 78 HCC patients diagnosed and treated from January 2010 to February 2012 in our hospital were divided into three groups: the combination group (39 cases) and the intervention group (39 cases) Patients in the treatment group were treated with hepatic artery interventional therapy alone. The combination group of Chinese medicine and traditional Chinese medicine Aidi injection combined with hepatic artery interventional therapy was used to treat the patients. The treatment effect, mean survival time, one-year survival rate and two-year survival rate were observed. Results: The therapeutic effect of combination group was significantly better than that of intervention group (P <0.05), and the average survival time was significantly longer than that of intervention group (P <0.05). The one-year survival rate and two-year survival rate were significantly higher than those of intervention group (P <0.05). Conclusion: Aidi injection combined with hepatic artery interventional therapy for hepatocellular carcinoma has a good clinical effect.